What top creators are saying about Johnson & Johnson(JNJ)

Mentioned as a competitor to Intuitive Surgical in the surgical robotics market.

Likely participant in medical R&D and supply chain response for the regional health crisis.

Monitoring expansion of Tremfya applications for chronic digestive conditions in the immunology space.

Experienced muted or negative price action compared to the broader market.

Identified as a key player in congressional lobbying with high sensitivity to healthcare legislation.

Belongs to a group of stable companies whose valuations have 'absolutely exploded.' The speaker is cautious to bearish on the stock at its current high valuation, calling it a 'mispricing'.

Johnson & Johnson is up 18% year-to-date, but is part of the broader consumer staples sector that is now viewed as historically expensive and overbought.

The company faces significant reputational risk and growing public distrust due to the COVID-19 vaccine rollout, with personal anecdotes linking the JNJ vaccine to serious side effects like blood clots.

The promotion of specialty drugs like Tremfaya highlights the importance of its high-margin pharmaceutical division, a key driver of profitability and financial strength for the company.

As a manufacturer of the ADHD drug Concerta, JNJ is exposed to the same broad regulatory and reputational risks as the sector, but was not singled out with a specific negative anecdote, giving it a more neutral risk profile in this context.

The company is expected to leverage AI to accelerate its development processes, representing a positive thematic driver.

Criticized for the baby powder scandal involving cancer-causing asbestos and being fined $5 billion for its role in the opioid crisis through deceptive marketing.

Sentiment is mixed to slightly positive. While a major drug (Stelara) faces decline, the company has strong growth drivers like Carvykti and a potential $5B+ blockbuster in IcoTropimra.

Mentioned only as a potential suitor for Abivax (ABVX), indicating broad interest from large pharma in Abivax's assets.

Spinning off the consumer health division into Kenvue is viewed as a successful de-risking strategy, isolating the parent company from potential liabilities related to the Tylenol brand.

Cited as the 'gold standard' for crisis management for its handling of the 1980s Tylenol incident, which demonstrates how prioritizing consumer trust can build immense long-term shareholder value.

News of a potential link between acetaminophen (Tylenol) use during pregnancy and autism represents a potential headwind and long-term risk factor due to possible sales impact and litigation.

Faces significant headline risk and potential for massive product liability lawsuits due to a possible link between its Tylenol brand and autism. The FDA is actively reviewing new data on the topic, posing a serious, near-term risk factor for the stock.

Insider sales were dismissed as low-signal events due to being part of scheduled plans or conducted by insiders with inconsistent and unreliable track records.

The CEO sold a massive $22.5 million worth of stock at an all-time high, and the CFO also sold recently. The CEO's only other sale preceded the stock's worst day ever, suggesting strong bearish sentiment from top leadership.

Showed resilience and posted gains during a broad market sell-off, acting as a defensive healthcare stock.

Mentioned as a US company re-exporting products from Ireland to take advantage of low taxes, which has angered the US and could lead to future tariffs or punitive measures as this issue was left out of the EU-US trade deal.

Used as an example of a solid company with strong fundamentals by an AI-cloned voice of Warren Buffett, but no active investment thesis is presented by the speaker.

The speaker has a neutral-to-negative view, stating their 'pipeline is pretty weak' and medical device growth is slow, speculating about a potential MedTech spin-off.

Successfully navigating the Stellara patent cliff with strong growth from its diverse portfolio, especially in oncology (Darzalex, Carvicti) and medtech. Raised full-year guidance indicates strong management confidence.

Grok V4 suggested it was 'undervalued,' but the host was highly skeptical, implying it is a poor recommendation facing headwinds.